Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
暂无分享,去创建一个
M. Avila | D. Xirodimas | F. Lopitz-Otsoa | R. Barrio | U. Mayor | M. Martínez-Chantar | M. Ávila | J. Crespo | J. Sutherland | J. Marin | J. Banales | R. Nogueiras | David Fernández-Ramos | T. Delgado | Jorge Simón | M. Azkargorta | X. Buqué | F. Elortza | P. Aspichueta | P. Iruzubieta | G. Baselli | Dimitris P. Xirodimas | E. Villa | Naroa Goikoetxea-Usandizaga | Marina Serrano-Maciá | Sofía Lachiondo-Ortega | Rubén Rodríguez-Agudo | M. Bizkarguenaga | Maria Mercado-Gómez | Luca Valenti | Maria J. Gonzalez-Rellan | Diego Sáenz de Urturi | Virginia Gutiérrez de Juan | T. C. Delgado | M. Martínez‐Chantar | Maria Mercado‐Gómez | Naroa Goikoetxea‐Usandizaga | Marina Serrano‐Maciá | Sofía Lachiondo‐Ortega | Xabier Buqué | F. Lopitz‐Otsoa
[1] D. Ding,et al. Regulation of Hepatic Metabolism and Cell Growth by the ATF/CREB Family of Transcription Factors , 2021, Diabetes.
[2] D. Xirodimas,et al. Proteome-wide identification of NEDD8 modification sites reveals distinct proteomes for canonical and atypical NEDDylation. , 2021, Cell reports.
[3] Jieun Seo,et al. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment , 2020, Cell Death & Disease.
[4] A. Sanyal,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.
[5] C. Hoogenraad,et al. Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics , 2020, Nature Structural & Molecular Biology.
[6] D. Prati,et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker , 2020, Gut.
[7] Xueying Zhang,et al. Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid β-oxidation , 2020, Proceedings of the National Academy of Sciences.
[8] A. Sanyal,et al. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. , 2020, Cell metabolism.
[9] F. Lopitz-Otsoa,et al. Ubiquitin-Like Post-Translational Modifications (Ubl-PTMs): Small Peptides with Huge Impact in Liver Fibrosis , 2019, Cells.
[10] N. Webster,et al. Degradation of splicing factor SRSF3 contributes to progressive liver disease. , 2019, The Journal of clinical investigation.
[11] A. Gartner,et al. The Balance between Mono- and NEDD8-Chains Controlled by NEDP1 upon DNA Damage Is a Regulatory Module of the HSP70 ATPase Activity , 2019, Cell reports.
[12] L. Henry,et al. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States , 2019, Hepatology communications.
[13] F. Tacke,et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.
[14] Ying E. Zhang,et al. Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis , 2018, PLoS biology.
[15] G. Shulman,et al. Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents , 2018, Hepatology.
[16] S. Pelusi,et al. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[17] F. Liu,et al. DEP domain–containing mTOR–interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute‐on‐chronic liver injury in alcoholic liver disease , 2018, Hepatology.
[18] F. Lopitz-Otsoa,et al. Neddylation, a novel paradigm in liver cancer. , 2018, Translational gastroenterology and hepatology.
[19] Shelly C. Lu,et al. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury , 2017, Nature Communications.
[20] Zhi‐Gang She,et al. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity , 2017, Hepatology.
[21] Shelly C. Lu,et al. Deregulated neddylation in liver fibrosis , 2017, Hepatology.
[22] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[23] T. T. Le,et al. Molecular classification of fatty liver by high‐throughput profiling of protein post‐translational modifications , 2016, The Journal of pathology.
[24] Ismael Torres,et al. The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation , 2016, Redox biology.
[25] S. Awasthi,et al. Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling. , 2015, Toxicology and applied pharmacology.
[26] Alexandre Caron,et al. The Roles of mTOR Complexes in Lipid Metabolism. , 2015, Annual review of nutrition.
[27] Ying Zhang,et al. Nrf2 regulates ROS production by mitochondria and NADPH oxidase , 2015, Biochimica et biophysica acta.
[28] Y. Harazono,et al. Gp78, an E3 Ubiquitin Ligase Acts as a Gatekeeper Suppressing Nonalcoholic Steatohepatitis (NASH) and Liver Cancer , 2015, PloS one.
[29] Shelly C. Lu,et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer , 2014, Oncotarget.
[30] S. Ricoult,et al. The multifaceted role of mTORC1 in the control of lipid metabolism , 2013, EMBO reports.
[31] H. El‐Serag,et al. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] Y. Sun,et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis , 2012, Cell Death and Disease.
[33] T. Slaga,et al. Inhibition of Neddylation Represses Lipopolysaccharide-induced Proinflammatory Cytokine Production in Macrophage Cells , 2012, The Journal of Biological Chemistry.
[34] Donna D. Zhang,et al. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. , 2010, Antioxidants & redox signaling.
[35] C. Ahn,et al. Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. , 2010, Cellular signalling.
[36] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[37] David M. Sabatini,et al. An Emerging Role of mTOR in Lipid Biosynthesis , 2009, Current Biology.
[38] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[39] Shelly C. Lu. Regulation of glutathione synthesis. , 2009, Molecular aspects of medicine.
[40] Daniel C. Scott,et al. Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation , 2008, Cell.
[41] G. Perdomo,et al. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. , 2007, Metabolism: clinical and experimental.
[42] H. Otu,et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. , 2007, American journal of physiology. Endocrinology and metabolism.
[43] R. E. Pitas,et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1 s⃞ Published, JLR Papers in Press, July 8, 2006. , 2006, Journal of Lipid Research.
[44] Paul J Thornalley,et al. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. , 2004, The Journal of nutrition.
[45] K. Itoh,et al. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. , 2003, The Biochemical journal.
[46] C. Kellendonk,et al. Hepatocyte‐specific expression of Cre recombinase , 2000, Genesis.
[47] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.